Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: A phase I Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 236-239

  Rose, Peter G ^a,b   Markman, Maurie ^c   Bell, Jeffrey G ^d,e   Fusco, Nancy L ^f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e RIVERSIDE METHODIST HOSPITAL   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Dose limiting toxicities; Etoposide; Second line treatment; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; TOPOISOMERASE I INHIBITOR; TOPOISOMERASE II INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LONG TERM CARE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TOPOTECAN;

EID: 33646891067     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.003     Document Type: Article

References (25)

1. Hoskins P.J., and Swenerton K.D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 60-63
2. Rose P.G., Blessing J.A., Mayer A.R., and Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16 (1998) 405-410
3. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15 (1997) 987-993
4. Gordon A.N., Granai C.O., Rose P.G., et al. Phase II study of Stealth® Liposomal Doxorubicin (Doxil®) in platinum and paclitaxel refractory epithelial ovarian cancer. J. Clin. Oncol. 18 (2000) 2957-2962
5. Bookman M., Malstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 (1998) 3345-3352
6. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., and Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66 (1997) 480-486
7. Shapiro J.D., Millward M.J., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63 (1996) 89-93
8. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J. Clin. Oncol. 14 (1996) 1545-1551
9. Rustin G.J., Nelstrop A.E., and Tuxen M.K. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann. Oncol. 7 (1996) 361-364
10. Johnson R., McCabe F., and Yu Y. Combination regimens with topotecan in animal models. Ann. Oncol. 3 (1992) 85
11. Whitacre C.M., Zborowska E., Gordon N.H., Mackkay W., and Berger N.A. Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. 57 (1997) 1425-1428
12. Gupta E., Toppmeyer D., Zamek R., Much J., Ibrahim N., et al. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Ther. 1 (1998) 292
13. Hammond L.A., Eckardt J.R., Ganapathi R., Burris H.A., Rodriguez G.A., et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin. Cancer Res. 4 (1998) 1459-1467
14. Schellens J.H., Cremers G.J., Beijnen J.H., et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer 73 (1996) 1268-1271
15. Zamboni W.C., Bowman L.C., Tan M., et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother. Pharmacol. 43 (1999) 454-460
16. Hochster H., Wadler S., Runowicz C., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. 17 (1999) 2553-2561
17. Herben V.M., ten Bokkel Huinink W.W., Dubbelman A.C., et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br. J. Cancer 76 (1997) 1395-1397
18. Mok T.S., Wong H., Zee B., et al. A phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer 95 (2002) 1551-1559
19. Crump M., Couban S., Meyer R., et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk. Lymphoma 43 (2002) 1581-1587
20. Ganem G., Gladieff L., Guastalla J.P., et al. Sequential topotecan (T) and etoposide (E) in pretreated ovarian cancer patients: a GINECO phase II study. Proc. ASCO 17 (1998) 355a [Abstract]
21. Levitt N.C., Propper D.J., Madhusudan S., et al. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Br. J. Cancer 93 (2005) 60-69
22. Gronlund B., Engelholm S.A., Horvath G., Maenpaa J., and Ridderheim M. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. Cancer 103 (2005) 1388-1396
23. Sood A.K., Lush R., Geisler J.P., et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin. Cancer Res. 10 (2004) 6080-6085
24. Sehouli J., Sommer H., Glare P., et al. Randomized phase III trial: topotecan versus topotecan/etoposide versus topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. Proc. ASCO 23 (2004) 482a [Abstract]
25. Morris R.T. Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. 90 (2003) S34-S38